CN102238962B - 抗膜铁转运蛋白1单克隆抗体及其用途 - Google Patents

抗膜铁转运蛋白1单克隆抗体及其用途 Download PDF

Info

Publication number
CN102238962B
CN102238962B CN200980148354.8A CN200980148354A CN102238962B CN 102238962 B CN102238962 B CN 102238962B CN 200980148354 A CN200980148354 A CN 200980148354A CN 102238962 B CN102238962 B CN 102238962B
Authority
CN
China
Prior art keywords
seq
fpn1
human
aminoacid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980148354.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN102238962A (zh
Inventor
D·D·M·梁
P·栾
J·V·马尼塔
唐鹰
D·R·威彻
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN102238962A publication Critical patent/CN102238962A/zh
Application granted granted Critical
Publication of CN102238962B publication Critical patent/CN102238962B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN200980148354.8A 2008-12-05 2009-12-01 抗膜铁转运蛋白1单克隆抗体及其用途 Expired - Fee Related CN102238962B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12007608P 2008-12-05 2008-12-05
US61/120,076 2008-12-05
US23981809P 2009-09-04 2009-09-04
US61/239,818 2009-09-04
PCT/US2009/066187 WO2010065496A1 (en) 2008-12-05 2009-12-01 Anti-ferroportin 1 monoclonal antibodies and uses thereof

Publications (2)

Publication Number Publication Date
CN102238962A CN102238962A (zh) 2011-11-09
CN102238962B true CN102238962B (zh) 2014-02-12

Family

ID=41683589

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980148354.8A Expired - Fee Related CN102238962B (zh) 2008-12-05 2009-12-01 抗膜铁转运蛋白1单克隆抗体及其用途

Country Status (25)

Country Link
EP (1) EP2373335B1 (cg-RX-API-DMAC7.html)
JP (1) JP5713917B2 (cg-RX-API-DMAC7.html)
KR (1) KR101353117B1 (cg-RX-API-DMAC7.html)
CN (1) CN102238962B (cg-RX-API-DMAC7.html)
AR (1) AR074398A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009322587B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0922288A2 (cg-RX-API-DMAC7.html)
CA (1) CA2745618C (cg-RX-API-DMAC7.html)
CY (1) CY1117355T1 (cg-RX-API-DMAC7.html)
DK (1) DK2373335T3 (cg-RX-API-DMAC7.html)
EA (1) EA020472B1 (cg-RX-API-DMAC7.html)
ES (1) ES2566343T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20160302T1 (cg-RX-API-DMAC7.html)
HU (1) HUE028585T2 (cg-RX-API-DMAC7.html)
IL (1) IL212731A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011005939A (cg-RX-API-DMAC7.html)
NZ (1) NZ592545A (cg-RX-API-DMAC7.html)
PA (1) PA8849601A1 (cg-RX-API-DMAC7.html)
PL (1) PL2373335T3 (cg-RX-API-DMAC7.html)
SG (1) SG171960A1 (cg-RX-API-DMAC7.html)
SI (1) SI2373335T1 (cg-RX-API-DMAC7.html)
TW (1) TW201023891A (cg-RX-API-DMAC7.html)
UA (1) UA104741C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010065496A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201103941B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014027905A2 (pt) * 2012-05-14 2017-06-27 Genentech Inc anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico.
WO2019213016A1 (en) 2018-04-30 2019-11-07 The Children's Hospital Of Philadelphia Methods of improving anemias by combining agents
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
CN110806486B (zh) * 2019-11-23 2023-03-21 中南大学湘雅三医院 Mafg/as1/pcbp2/fpn1调控轴作为靶位点检测试剂的应用
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CN113980987A (zh) * 2021-12-06 2022-01-28 上海市农业科学院 一种提高植物抗镍性能的PgIREG1S和AlATP-PRTS双基因组及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166448B1 (en) * 1999-05-10 2007-01-23 Children's Medical Center Corproation Ferroportin1 nucleic acids and proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1319221B1 (it) * 2000-10-17 2003-09-26 Antonello Pietrangelo Mutazioni nel gene della ferroportina 1 associata ad emocromatosiereditaria.
EP2803675A3 (en) * 2008-01-25 2014-12-24 Amgen, Inc Ferroportin antibodies and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166448B1 (en) * 1999-05-10 2007-01-23 Children's Medical Center Corproation Ferroportin1 nucleic acids and proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Iron uptake and metabolism in the new millennium;Louise L. Dunn,et al;《TRENDS in Cell Biology》;20061227;第17卷(第2期);93-100 *
Regulation of Iron metabolism;Elizabeta Nemeth and Tomas Ganz;《Annu. Rev. Nutr》;20061231;第26卷(第2期);323-342 *

Also Published As

Publication number Publication date
WO2010065496A1 (en) 2010-06-10
AR074398A1 (es) 2011-01-12
JP2012510814A (ja) 2012-05-17
CA2745618C (en) 2014-06-10
JP5713917B2 (ja) 2015-05-07
CA2745618A1 (en) 2010-06-10
AU2009322587A1 (en) 2011-07-28
EA201170764A1 (ru) 2011-12-30
HUE028585T2 (en) 2016-12-28
HK1158977A1 (zh) 2012-07-27
KR20110084996A (ko) 2011-07-26
UA104741C2 (uk) 2014-03-11
AU2009322587B2 (en) 2013-09-26
CN102238962A (zh) 2011-11-09
SG171960A1 (en) 2011-07-28
KR101353117B1 (ko) 2014-02-17
EP2373335A1 (en) 2011-10-12
MX2011005939A (es) 2011-06-27
IL212731A0 (en) 2011-07-31
TW201023891A (en) 2010-07-01
PL2373335T3 (pl) 2016-08-31
SI2373335T1 (sl) 2016-04-29
HRP20160302T1 (hr) 2016-04-22
NZ592545A (en) 2012-12-21
EA020472B1 (ru) 2014-11-28
ES2566343T3 (es) 2016-04-12
BRPI0922288A2 (pt) 2018-08-28
DK2373335T3 (en) 2016-05-02
ZA201103941B (en) 2012-11-28
PA8849601A1 (es) 2010-07-27
EP2373335B1 (en) 2016-02-24
CY1117355T1 (el) 2017-04-26

Similar Documents

Publication Publication Date Title
US8679497B2 (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
AU2010286518B2 (en) Therapeutic DLL4 binding proteins
CN104936981B (zh) Il‑17a结合物及其用途
EP3087097B1 (en) Multifunctional antibodies binding to egfr and met
AU2019201141B2 (en) Novel antibody binding to TFPI and composition comprising the same
CN113164766A (zh) RGMc选择性抑制剂及其用途
CN105111308A (zh) 抗N3pGlu淀粉样蛋白BETA肽抗体及其用途
TW201525004A (zh) 結合前蛋白轉化酶枯草桿菌蛋白酶加工酶9型之人類抗原結合蛋白
KR20180044441A (ko) 치료학적 dll4 결합 단백질
JP2023537422A (ja) Il-11の抗体及びその使用
CN108473568A (zh) 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子
KR20190021244A (ko) 항-axl 길항성 항체
JP5713917B2 (ja) 抗フェロポーチン1モノクローナル抗体およびその使用
KR20250153216A (ko) Fap/cd40 결합 분자의 약학적 조성물 및 이의 의약적 용도
KR20220007128A (ko) 항-sema3a 항체 및 눈 또는 안구 질환 치료를 위한 이의 용도
US20260098096A1 (en) Anti-ccr8 antibodies
CA3205846A1 (en) Anti-pdgf-b antibodies and mehods of use for treating pulmonary arterial hypertension (pah)
JPWO2019054460A1 (ja) 抗ramp2抗体
HK1158977B (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
WO2025113639A1 (zh) 抗gdf15的抗体及其方法和用途
CN120437287A (zh) 一种包含特异性结合gucy2c和cd3的双特异性抗体的药物组合物
WO2025152915A1 (zh) 抗肾上腺髓质素抗体在预防或治疗脑卒中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140212

Termination date: 20171201

CF01 Termination of patent right due to non-payment of annual fee